

# Pfizer-sponsored symposium at ISICEM 2022

Wednesday, 23<sup>rd</sup> March 2022  
12:30–13:30 (CET)  
Gold Hall



## The art of clinical decision-making in the ICU: challenging case studies of MDR Gram-negative infections

By considering the challenging scenarios that face the ICU physician and influence treatment outcomes, this meeting aims to:

- Recognise the effect of the evolving MDR Gram-negative epidemiology in the era of COVID-19
- Discuss the impact of improving early identification of ICU patients who have limited treatment options
- Highlight how the evidence generated from real-world data can support decision-making
- Revisit current approaches to optimising antimicrobial dosing

## Agenda

Chair: Jan De Waele (Belgium)

- 
- 12:30 »**                      **Welcome and introduction**  
Jan De Waele
- 
- 12:35 »**                      **The treatment journey when options are limited**  
Michele Bartoletti (Italy)
- 
- 12:55 »**                      **A physician's decisions when managing patients with HAP/VAP**  
Luke Moore (United Kingdom)
- 
- 13:15 »**                      **Panel discussion and Q&A**  
All faculty
- 
- 13:25 »**                      **Summary and close**  
Jan De Waele
- 

HAP/VAP, hospital-acquired pneumonia/ventilator-associated pneumonia; ICU, intensive care unit; MDR, multidrug-resistant.

This symposium is initiated, organised and funded by Pfizer Inc.  
220208; Date of Preparation: February 2022.  
©2022 Pfizer Inc. All rights reserved.

